The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial [17] showed no increase in clinical CV events with insulin glargine for early T2DM after 6.2 years, and a substudy of the ORIGIN, the Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE) [18] also revealed that long-term treatment with insulin might result in CV event reduction. This evidence concerns the gene INS and type 2 diabetes mellitus.